Convenient and Live Movement (CALM) for Women Undergoing Breast Cancer Treatment: Challenges and Recommendations for Internet-based Yoga Research
Overview
Affiliations
Objective: To conduct a pilot trial of internet-based, cancer-adapted yoga for women receiving breast cancer treatment.
Design: Women undergoing radiation or chemotherapy for breast cancer were recruited for 12, 75-min, biweekly, cancer-adapted yoga classes delivered via internet-based, multipoint videoconferencing. Data were collected on feasibility and acceptability, including qualitative feedback from participants and the yoga instructor.
Results: Among 42 women approached, 13 declined eligibility screening, and 23 were ineligible. All 6 women who were eligible provided consent, but 2 withdrew prior to beginning yoga classes. The remaining 4 participants attended 1-11 of 12 online yoga classes. In post-intervention interviews, participants and the instructor agreed that internet-based yoga classes hold great potential for increasing access and improving psychological outcomes in adults with cancer. Qualitative feedback from participants revealed suggestions for future trials of internet-based, cancer-adapted yoga classes, including: continued use of group format; offering more varied class times to accommodate patients' demanding schedules and fluctuating symptoms; enrolling patients after they have acclimated to or completed cancer treatment; streamlining the technology interface; and careful attention to participant burden when designing surveys/forms. The instructor recommended closed session courses, as opposed to rolling enrollment; teaching the same modified poses for all participants, rather than individual tailoring; and using a large screen to allow closer monitoring of students' class experience.
Conclusions: Internet delivery may increase patients' access to cancer-adapted yoga classes, but cancer-related and technological barriers remain. This study informs how to optimally design yoga classes, technology, and research procedures to maximize feasibility and acceptability in future trials.
Wurz A, McLaughlin E, Janzen A, Cripps H, Huang L, Molina H Glob Adv Integr Med Health. 2024; 13:27536130241305130.
PMID: 39717073 PMC: 11664516. DOI: 10.1177/27536130241305130.
Feighan L, MacDonald-Wicks L, Callister R, Surjan Y Support Care Cancer. 2024; 32(11):745.
PMID: 39441426 PMC: 11499338. DOI: 10.1007/s00520-024-08933-1.
Pham C, Hildebrand C, Tarasovsky G, Purcell N, Seal K, Nicosia F Glob Adv Integr Med Health. 2024; 13:27536130241268107.
PMID: 39429898 PMC: 11489906. DOI: 10.1177/27536130241268107.
Rabe A, Kessler A, Hagemann C, Schubert J, Jentschke E BMJ Open. 2024; 14(10):e075698.
PMID: 39414288 PMC: 11487817. DOI: 10.1136/bmjopen-2023-075698.
Andreae S, Casey T, Mross P, Mezera M, Mortensen A, Pickett K J Healthy Eat Act Living. 2024; 4(2):92-106.
PMID: 39372062 PMC: 11448911.